Details of Drug-Metabolizing Enzyme (DME)

General Information of Drug-Metabolizing Enzyme (DME) (ID: DEPKLMQ)

DME Name	Cytochrome P450 2B6 (CYP2B6)
Synonyms	Cytochrome P450 family 2 subfamily B member 6; Cytochrome P450 IIB1; CYP2B6; CYPIIB6
Gene Name	CYP2B6
UniProt ID	CP2B6_HUMAN
INTEDE ID	DME0020
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Gene ID	1555
EC Number	EC: 1.14.14.1 Oxidoreductase Oxygen paired donor oxidoreductase Flavin/flavoprotein donor oxidoreductase EC: 1.14.14.1
Lineage	Species: Homo sapiens Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens
Sequence	MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRGLLKSFLRFRE KYGDVFTVHLGPRPVVMLCGVEAIREALVDKAEAFSGRGKIAMVDPFFRGYGVIFANGNR WKVLRRFSVTTMRDFGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIIC SIVFGKRFHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQE INAYIGHSVEKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLSLFFAGT ETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPYTEAVIYEIQRFS DLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEKPDAFNPDHFLDANGAL KKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVAPEDIDLTPQECGVGKI PPTYQIRFLPR
Function	This enzyme is involved in the metabolism of endocannabinoids and steroids. It catalyzes the epoxidation of double bonds of arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15- epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs). It hydroxylates steroid hormones, including testosterone at C-16 and estrogens at C-2 and plays a role in the oxidative metabolism of xenobiotics, including plant lipids and drugs.
KEGG Pathway	Arachidonic acid metabolism (hsa00590 ) Drug metabolism - cytochrome P450 (hsa00982 ) Metabolic pathways (hsa01100 ) Metabolism of xenobiotics by cytochrome P450 (hsa00980 ) Retinol metabolism (hsa00830 )
Reactome Pathway	Fatty acids (R-HSA-211935 ) Xenobiotics (R-HSA-211981 ) CYP2E1 reactions (R-HSA-211999 )

Molecular Interaction Atlas (MIA) of This DME

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DME

86 Approved Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[1]
Artemether	DM48QOT	Malaria	1F40-1F45	Approved	[2]
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[3]
Benzphetamine	DMIJATC	Obesity	5B81	Approved	[4]
Brivaracetam	DMSEPK8	Complex partial seizure	8A68.0	Approved	[5]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[6]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[7]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[8]
Cenobamate	DM8KLU9	Complex partial seizure	8A68.0	Approved	[9]
Cinnarizine	DM7U5QJ	Meniere disease	AB31.0	Approved	[10]
Cisapride	DMY7PED	Gastroesophageal reflux disease	DA22.Z	Approved	[11]
Clobazam - Lundbeck	DMW1OQ0	Anxiety disorder	6B00-6B0Z	Approved	[12]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[13]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[14]
Clotiazepam	DM59AZT	Anxiety disorder	6B00-6B0Z	Approved	[15]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[16]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[17]
Dextromethorphan	DMUDJZM	Allergic rhinitis	CA08.0	Approved	[18]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[19]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[20]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[21]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[22]
Enasidenib	DM8QXOC	N. A.	N. A.	Approved	[23]
Epinastine	DMX0K3Q	Allergic conjunctivitis	9A60.02	Approved	[24]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[25]
Fexinidazole	DMOYE70	African trypanosomiasis	1F51	Approved	[26]
Flunitrazepam	DMGR5Z3	Insomnia	7A00-7A0Z	Approved	[27]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[28]
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[29]
Hydrocodone bitartrate	DMIAPBE	N. A.	N. A.	Approved	[30]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[31]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[32]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[17]
Isoflurane	DMY6T31	Anaesthesia	9A78.6	Approved	[33]
Istradefylline	DM20VSK	Parkinson disease	8A00.0	Approved	[34]
Ketamine	DMT5HA4	Anaesthesia	9A78.6	Approved	[35]
Ketobemidone	DMM3L6Z	Pain	MG30-MG3Z	Approved	[36]
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[2]
Loperamide	DMOJZQ9	Diarrhea	ME05.1	Approved	[37]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[38]
Lorcaserin	DMG6OYJ	Obesity	5B81	Approved	[39]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[40]
Meperidine	DMX4GND	Pain	MG30-MG3Z	Approved	[2]
Mephenytoin	DM5UGDK	Epilepsy	8A60-8A68	Approved	[10]
Methadone	DMTW6IU	Advanced cancer	2A00-2F9Z	Approved	[41]
Methoxyflurane	DML0RAE	Anaesthesia	9A78.6	Approved	[42]
Methylphenobarbital	DMDSWAG	Anxiety		Approved	[43]
Methyltestosterone	DMWLFGO	Advanced cancer	2A00-2F9Z	Approved	[44]
Mexiletine	DMCTE9R	Ventricular tachycardia	BC71	Approved	[45]
Mianserin	DMVKA4O	Depression	6A70-6A7Z	Approved	[29]
Midazolam	DMXOELT	Agitation	6A70.3	Approved	[46]
MLN9708	DMCMETN	Amyloidosis	5D00	Approved	[47]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[48]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[49]
Ospemifene	DMC4GEI	Dyspareunia	GA12	Approved	[50]
Perhexiline	DMINO7Z	Angina pectoris	BA40	Approved	[51]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[52]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[8]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[53]
Prasugrel	DM7MT6E	Acute coronary syndrome	BA41	Approved	[54]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[29]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[55]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[56]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[22]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[57]
Ropivacaine	DMSPJG2	Anaesthesia	9A78.6	Approved	[33]
Selegiline Hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[58]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[59]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[33]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[60]
Temazepam	DM02A65	Insomnia	7A00-7A0Z	Approved	[61]
Testosterone cypionate	DMC1TEV	N. A.	N. A.	Approved	[2]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[2]
Testosterone undecanoate	DMZO10Y	Hypogonadism	5A61.0	Approved	[2]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[62]
Tramadol	DMRQD04	Osteoarthritis	FA00-FA05	Approved	[63]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[33]
Trifarotene	DMOL793	Acne vulgaris	ED80	Approved	[64]
Trofosfamide	DMHB2C3	Non-hodgkin lymphoma	2B33.5	Approved	[65]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[2]
Velpatasvir	DMGF8ZQ	N. A.	N. A.	Approved	[66]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[33]
Vonoprazan	DMO6315	Helicobacter infection	DA42-DA63	Approved	[67]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[68]
Voxelotor	DMCS6M5	Sickle-cell disorder	3A51	Approved	[69]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[70]
------------------------------------------------------------------------------------


⏷ Show the Full List of 86 Approved Drug(s)

6 Clinical Trial Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clomethiazole	DMSPN58	Stroke	8B20	Phase 3	[33]
Esketamine	DMVU687	Depression	6A70-6A7Z	Phase 3	[35]
BMS 650032	DMQI43G	Hepatitis C virus infection	1E51.1	Phase 2	[71]
Dexloxiglumide	DM52HUD	Pancreatic malfunction	DC30-DC3Z	Phase 2	[72]
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[73]
H3B-6545	DMIFCY2	Breast cancer	2C60-2C65	Phase 1/2	[74]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Clinical Trial Drug(s)

3 Discontinued Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Seratrodast	DMPNTDL	Allergic asthma	CA23.0	Discontinued in Phase 3	[10]
FCP-3P1	DMTQLIJ	Arteriosclerosis	BD40	Discontinued in Phase 2	[75]
Banoxantrone	DMK5I07	Acute lymphoblastic leukaemia	2A85	Discontinued in Phase 1	[76]
------------------------------------------------------------------------------------

3 Investigative Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethylmorphine	DM0YROF	Discovery agent	N.A.	Investigative	[19]
Levoverbenone	DMV3P89	N. A.	N. A.	Investigative	[77]
Phenazone	DMCE985	Discovery agent	N.A.	Investigative	[78]
------------------------------------------------------------------------------------

Molecular Expression Atlas (MEA) of This DME

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This DME

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Acute myelocytic leukaemia	2B33.1	Bone marrow	7.30E-02	-1.59E-02	-1.23E-01
Alopecia	ED70	Skin from scalp	5.59E-02	3.00E-01	3.61E-01
Alzheimer's disease	8A20	Entorhinal cortex	4.88E-01	-1.69E-05	-1.28E-04
Ankylosing spondylitis	FA92.0	Pheripheral blood	8.71E-02	-5.85E-02	-7.69E-01
Aortic stenosis	BB70	Calcified aortic valve	9.45E-01	-1.69E-02	-2.18E-02
Apnea	7A40	Hyperplastic tonsil	6.10E-01	-5.59E-02	-2.63E-01
Arthropathy	FA00-FA5Z	Peripheral blood	5.28E-02	9.71E-02	9.67E-01
Asthma	CA23	Nasal and bronchial airway	4.74E-01	2.25E-01	1.65E-01
Atopic dermatitis	EA80	Skin	3.49E-03	2.21E-02	2.17E-01
Autism	6A02	Whole blood	4.08E-01	-7.97E-02	-4.43E-01
Autoimmune uveitis	9A96	Peripheral monocyte	1.09E-01	-9.75E-02	-4.25E-01
Autosomal dominant monocytopenia	4B04	Whole blood	5.55E-01	3.64E-04	2.57E-03
Bacterial infection of gingival	1C1H	Gingival tissue	2.84E-01	2.08E-02	7.58E-02
Batten disease	5C56.1	Whole blood	5.75E-01	-8.69E-02	-8.50E-01
Behcet's disease	4A62	Peripheral blood	4.32E-01	7.38E-02	4.17E-01
Bipolar disorder	6A60-6A6Z	Prefrontal cortex	5.99E-01	1.92E-02	1.35E-01
Bladder cancer	2C94	Bladder tissue	6.20E-05	5.17E-01	3.18E+00
Breast cancer	2C60-2C6Z	Breast tissue	5.71E-03	5.36E-02	1.63E-01
Cardioembolic stroke	8B11.20	Whole blood	7.07E-01	-5.57E-02	-1.64E-01
Cervical cancer	2C77	Cervical tissue	2.02E-03	-1.26E-01	-6.18E-01
Childhood onset rheumatic disease	FA20.Z	Peripheral blood	7.58E-01	9.97E-03	6.67E-02
Chronic hepatitis C	1E51.1	Whole blood	8.60E-02	1.65E-01	8.28E-01
Chronic obstructive pulmonary disease	CA22	Lung tissue	2.10E-02	9.95E-02	3.65E-01
Chronic obstructive pulmonary disease	CA22	Small airway epithelium	2.07E-03	-2.31E-01	-5.10E-01
Chronic rhinosinusitis	CA0A	Sinus mucosa tissue	2.73E-03	-6.73E-01	-1.20E+00
Colon cancer	2B90	Colon tissue	7.11E-02	1.77E-01	2.56E-01
Coronary artery disease	BA80-BA8Z	Peripheral blood	4.85E-01	-1.16E-01	-6.57E-01
Diffuse large B-cell lymphoma	2A81	Tonsil tissue	8.81E-01	-4.25E-02	-1.66E-01
Endometriosis	GA10	Endometrium tissue	7.34E-01	-2.23E-02	-9.87E-02
Familial hypercholesterolemia	5C80.00	Peripheral blood	1.93E-01	-2.22E-02	-1.61E-01
Familial hypercholesterolemia	5C80.00	Whole blood	2.88E-03	-2.88E-01	-1.41E+00
Gastric cancer	2B72	Gastric tissue	1.70E-02	5.52E-02	5.02E-01
Glioblastopma	2A00.00	Nervous tissue	4.78E-02	4.13E-02	1.93E-01
Glioma	2A00.0Y-2A00.0Z	Brain stem tissue	6.41E-01	-4.80E-02	-3.07E-01
Glioma	2A00.0Y-2A00.0Z	White matter tissue	5.69E-05	-5.35E-01	-2.88E+00
Head and neck cancer	2D42	Head and neck tissue	7.41E-12	-2.61E-01	-3.81E-01
HIV-associated neurocognitive impairment	8A2Y-8A2Z	White matter tissue	3.54E-01	-2.05E-02	-1.25E-01
Huntington's disease	8A01.10	Whole blood	2.40E-01	-8.11E-02	-5.50E-01
Idiopathic pulmonary fibrosis	CB03.4	Lung tissue	8.91E-01	-3.14E-02	-1.42E-01
Immunodeficiency	4A00-4A20	Peripheral blood	5.27E-01	3.96E-02	3.97E-01
Influenza	1E30	Whole blood	2.05E-02	3.08E-01	2.67E+00
Interstitial cystitis	GC00.3	Bladder tissue	7.62E-01	5.13E-02	3.48E-01
Intracranial aneurysm	8B01.0	Intracranial artery	3.93E-01	-1.08E-02	-7.09E-02
Irritable bowel syndrome	DD91.0	Rectal colon tissue	8.55E-01	7.99E-02	2.21E-01
Ischemic stroke	8B11	Peripheral blood	1.88E-01	3.80E-02	1.69E-01
Juvenile idiopathic arthritis	FA24	Peripheral blood	1.46E-01	-4.36E-02	-1.36E-01
Lateral sclerosis	8B60.4	Skin	8.28E-01	-5.54E-02	-4.08E-01
Lateral sclerosis	8B60.4	Cervical spinal cord	2.35E-02	7.82E-02	4.89E-01
Liver cancer	2C12.0	Liver tissue	2.38E-13	-2.40E+00	-1.69E+00
Liver failure	DB99.7-DB99.8	Liver tissue	1.22E-03	-1.69E+00	-3.55E+00
Lung cancer	2C25	Lung tissue	2.81E-03	-9.34E-02	-3.57E-01
Lupus erythematosus	4A40	Whole blood	2.36E-06	6.59E-02	2.11E-01
Major depressive disorder	6A70-6A7Z	Hippocampus	5.79E-01	-1.30E-02	-9.78E-02
Major depressive disorder	6A70-6A7Z	Whole blood	3.00E-01	1.26E-01	3.74E-01
Melanoma	2C30	Skin	5.29E-04	-5.51E-01	-5.60E-01
Multiple myeloma	2A83.1	Peripheral blood	1.01E-01	5.77E-02	8.39E-01
Multiple myeloma	2A83.1	Bone marrow	2.88E-03	-6.19E-01	-1.74E+00
Multiple sclerosis	8A40	Plasmacytoid dendritic cells	3.97E-02	-1.72E-01	-9.29E-01
Myelodysplastic syndrome	2A36-2A3Z	Bone marrow	9.02E-01	1.35E-02	7.95E-02
Myelofibrosis	2A20.2	Whole blood	1.66E-01	-2.64E-02	-2.16E-01
Myocardial infarction	BA41-BA50	Peripheral blood	5.14E-01	5.05E-02	6.99E-02
Myopathy	8C70.6	Muscle tissue	7.06E-01	-4.55E-02	-2.54E-01
Neonatal sepsis	KA60	Whole blood	8.52E-01	-9.47E-03	-5.16E-02
Neuroectodermal tumour	2A00.11	Brain stem tissue	7.27E-03	-3.02E-01	-1.04E+00
Non-alcoholic fatty liver disease	DB92	Liver tissue	2.98E-01	3.67E-01	5.18E-01
Obesity related type 2 diabetes	5A11	Omental adipose tissue	3.11E-01	9.55E-02	1.62E+00
Olive pollen allergy	CA08.00	Peripheral blood	6.86E-01	1.54E-01	4.86E-01
Oral cancer	2B6E	Oral tissue	8.41E-01	-4.49E-02	-1.67E-01
Osteoarthritis	FA00-FA0Z	Synovial tissue	1.64E-01	1.53E-01	1.14E+00
Osteoporosis	FB83.1	Bone marrow	4.17E-01	-2.70E-02	-2.65E-01
Ovarian cancer	2C73	Ovarian tissue	3.79E-01	-3.97E-02	-1.93E-01
Pancreatic cancer	2C10	Pancreas	1.10E-02	1.91E-02	9.50E-02
Parkinson's disease	8A00.0	Substantia nigra tissue	4.32E-01	4.39E-02	4.30E-01
Pediatric respiratory syncytial virus infection	CA40.11	Peripheral blood	4.96E-03	-1.55E-01	-1.47E+00
Pituitary cancer	2D12	Pituitary tissue	7.65E-01	3.20E-02	1.39E-01
Pituitary gonadotrope tumour	2D12	Pituitary tissue	8.71E-01	7.12E-03	3.68E-02
Polycystic ovary syndrome	5A80.1	Vastus lateralis muscle	3.86E-02	3.52E-02	6.08E-01
Polycythemia vera	2A20.4	Whole blood	5.18E-01	-3.02E-02	-2.12E-01
Pompe disease	5C51.3	Biceps muscle	7.33E-03	-2.03E-01	-8.96E-01
Preterm birth	KA21.4Z	Myometrium	5.67E-01	-4.10E-02	-5.31E-01
Prostate cancer	2C82	Prostate	1.97E-02	1.25E-01	3.51E-01
Psoriasis	EA90	Skin	1.62E-02	1.07E-01	4.44E-01
Rectal cancer	2B92	Rectal colon tissue	2.22E-02	5.21E-01	1.32E+00
Renal cancer	2C90-2C91	Kidney	3.82E-03	-4.83E-01	-1.24E+00
Retinoblastoma	2D02.2	Uvea	2.84E-01	4.60E-02	4.01E-01
Rheumatoid arthritis	FA20	Synovial tissue	7.53E-01	1.26E-01	4.92E-01
Rhinovirus infection	CA42.1	Nasal epithelium tissue	1.43E-01	1.84E-02	5.34E-02
Schizophrenia	6A20	Prefrontal cortex	9.90E-01	3.10E-03	1.75E-02
Schizophrenia	6A20	Superior temporal cortex	5.35E-01	1.10E-02	1.19E-01
Scleroderma	4A42.Z	Whole blood	4.10E-07	3.21E-01	3.95E+00
Seizure	8A60-8A6Z	Whole blood	7.40E-02	-7.76E-02	-4.64E-01
Sensitive skin	EK0Z	Skin	5.29E-01	-2.88E-02	-7.39E-02
Sepsis with septic shock	1G41	Whole blood	5.42E-11	1.25E-01	7.17E-01
Shwachman-Diamond syndrome	3A70.0	Bone marrow	3.47E-02	2.12E-01	7.38E-01
Sickle cell disease	3A51.0-3A51.3	Peripheral blood	1.52E-05	1.99E-01	3.17E+00
Simpson golabi behmel syndrome	LD2C	Adipose tissue	3.51E-01	4.13E-02	2.86E-01
Sjogren's syndrome	4A43.2	Salivary gland tissue	6.09E-02	-1.44E-01	-1.93E+00
Skin cancer	2C30-2C3Z	Skin	8.25E-05	1.47E-01	3.09E-01
Thrombocythemia	3B63	Whole blood	3.39E-01	-1.22E-02	-9.58E-02
Thrombocytopenia	3B64	Whole blood	2.11E-01	-7.34E-02	-3.14E-01
Thyroid cancer	2D10	Thyroid	1.25E-01	-7.02E-02	-2.81E-01
Tibial muscular dystrophy	8C75	Muscle tissue	7.03E-01	3.69E-02	1.86E-01
Tuberous sclerosis complex	LD2D.2	Perituberal tissue	1.94E-01	1.29E-01	7.28E-01
Type 2 diabetes	5A11	Liver tissue	2.05E-01	-1.49E-01	-3.36E-01
Ureter cancer	2C92	Urothelium	7.19E-01	-5.25E-02	-4.77E-01
Uterine cancer	2C78	Endometrium tissue	2.28E-01	2.15E-03	7.85E-03
Vitiligo	ED63.0	Skin	7.19E-01	-2.31E-01	-1.10E+00
------------------------------------------------------------------------------------


⏷ Show the Full List of DME Expression Under 107 Diseases

The Drug Therapeutic Target (DTT) Role of This DME

DME DTT Name	Cytochrome P450 2B6 (CYP2B6) DTT Info
DME DTT Type	Literature-reported

References

1	Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
2	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
3	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
4	Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab Dispos. 2009 Apr;37(4):745-52.
5	Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45.
6	Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. Basic Clin Pharmacol Toxicol. 2019 Aug;125(2):123-132.
7	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
8	Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58.
9	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
10	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
12	In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
13	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
14	Clopidogrel pathway. Pharmacogenet Genomics. 2010 Jul;20(7):463-5.
15	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
16	The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):814-22.
17	Drugs that may have potential CYP2B6 interactions.
18	Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos. 1999 Oct;20(7):341-6.
19	Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol. 1998 May 15;55(10):1633-40.
20	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
21	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
22	Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ consortium induction working group-an industry perspective. Drug Metab Dispos. 2016 Oct;44(10):1720-30.
23	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
24	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
25	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
26	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
27	CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40.
28	Molecular characterization of CYP2B6 substrates. Curr Drug Metab. 2008 Jun;9(5):363-73.
29	Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
30	FDA label of Hydrocodone bitartrate. The 2020 official website of the U.S. Food and Drug Administration.
31	A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem. 2003 Apr 18;278(16):14146-52.
32	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
33	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
34	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
35	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
36	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
37	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
38	Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009 Aug;3(3):162-70.
39	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
40	Malathion bioactivation in the human liver: the contribution of different cytochrome p450 isoforms. Drug Metab Dispos. 2005 Mar;33(3):295-302.
41	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
42	Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
43	Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans. Pharmacogenetics. 2004 Aug;14(8):549-56.
44	Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl. 1999 Nov 26;735(1):73-83.
45	Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine. Xenobiotica. 2003 Jan;33(1):13-25.
46	Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther. 1998 Sep;286(3):1253-9.
47	NINLARO- European Medicines Agency - European Union
48	RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):423-31.
49	Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
50	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
51	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
52	Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol. 2007;21(4):182-6.
53	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
54	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
55	Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
56	Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006 Jul;80(1):75-84.
57	FDA Label of Romidepsin. The 2020 official website of the U.S. Food and Drug Administration.
58	Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem Biol Interact. 2015 Mar 25;230:9-20.
59	Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016 Apr;38(2):388-94.
60	Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
61	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
62	Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol. 2000;14(3):140-7.
63	Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
64	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
65	Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. Cancer Chemother Pharmacol. 1999;44(4):327-34.
66	Epclusa- European Medicines Agency - European Union
67	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
68	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
69	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
70	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
71	Australian Public Assessment Report for asunaprevir.
72	Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide. Br J Clin Pharmacol. 2005 Nov;60(5):498-507.
73	Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 2008 Mar;36(3):561-70.
74	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
75	Conformational adaptation of human cytochrome P450 2B6 and rabbit cytochrome P450 2B4 revealed upon binding multiple amlodipine molecules. Biochemistry. 2012 Sep 18;51(37):7225-38.
76	Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther. 2006 Jun;13(6):598-605.
77	Roles of human CYP2A6 and 2B6 and rat CYP2C11 and 2B1 in the 10-hydroxylation of (-)-verbenone by liver microsomes. Drug Metab Dispos. 2003 Aug;31(8):1049-53.
78	Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos. 1997 Mar;25(3):390-3.